Replies to post #565632 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Here are the facts that contradict your statement.

Operational updates for the third quarter ended September 30, 2022:

As of September 30, 2022, there were 3,420 active patients on therapy. Active patients from North America, EMEA and Japan contributed 2,181, 885 and 354 active patients, respectively.
1,389 prescriptions were received in the quarter. Prescriptions from North America, EMEA and Japan contributed 978, 332 and 79 prescriptions, respectively.


Operational updates for the year and quarter ended December 31, 2022:
As of December 31, 2022, there were 3,430 active patients on therapy. Active patients from North America, EMEA and Japan contributed 2,191, 870, and 369, respectively.
1,373 prescriptions were received in the quarter. Prescriptions from North America, EMEA and Japan contributed 956, 312, and 105, respectively.

[Roman516]

H-G, but the reality is that the Regulators already understand that DCVax-L does in fact work and it has already been proven multiple times. In fact, DCVax-L has virtually zero side effects compared to vast array of side effects from current treatment products like the high frequency transducer helmet, IMPO. All the best!
Perhaps when DCVax-L is approved, the NCCN will consider designated DCVax-L as the new first line therapy, IMPO. [color=red][/color]